関節リウマチの最新薬物療法

出版社： 医学と看護社
著者：
発行日： 2012-04-10
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784906829002
電子書籍版： 2012-04-10 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,180 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,180 円(税込)

購入する

商品紹介

本書は、臨床のエビデンスと著者の自験を織り交ぜ、安全・効果的な治療を行える実践の書とした。

目次

  • 関節リウマチの最新薬物療法

    ―目次―

    1．関節リウマチの病態
    2．関節リウマチ診療における検査
    3．活動性や病期の評価法
    4．関節リウマチの診断から治療戦略
    5．日常リウマチ診療における対応
    6．妊娠、授乳に関わる関節リウマチ治療
    7．血管炎を伴う関節リウマチと関節外症状
    8．リウマチ診療における抗炎症薬とステロイドの使い方
    9．生物学的製剤を含めた抗リウマチ薬の使用法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1. 関節リウマチの病態

P.17 掲載の参考文献
1) Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell 1996 ; 85 (3) : 311-8.
PubMed
2) Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, Ollier WE. Twin concordance rates for rheumatoid arthritis : results from a nationwide study. Br J Rheumatol 1993 ; 32 (10) : 903-7.
PubMed
3) Aho K, Koskenvuo M, Tuominen J, K aprio J. Occurrence of rheumatoid arthritis in a nationwide series of twins. J Rheumatol 1986 ; 13 (5) : 899-902.
 
4) Wilder RL, Remmers EF, Kawahito Y, Gulko PS, C annon GW, Griffiths M M. Genetic factors regulating experimental arthritis in mice and rats. Curr Dir Autoimmun 1999 ; 1 : 121-65.
 
5) Wakitani S, Imoto K, Murata N, Oonishi H, Ochi T, Yoneda M. An association between the natural course of shoulder joint destruction in rheumatoid arthritis and HLA-DRB1*0405 in Japanese patients. Scand J Rheumatol 1998 ; 27 (2) : 146-8.
PubMed
6) Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis : an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987 ; 30 : 1205-13.
PubMed
7) Lanchbury JS, Panayi GS. Genetics of RA : the HLA shared epitope hypothesis and its implications. Br J Rheumatol 1991 ; 30 Suppl 2 : 6-9.
 
8) Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam A P, A lexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, Conn MT, Chang M, Chang SY, Saiki RK, Catanese JJ, Leong DU, Garcia VE, McAllister LB, Jeffery DA, Lee AT, Batliwalla F, Remmers E, Criswell LA, Seldin MF, Kastner DL, Amos CI, Sninsky JJ, Gregersen PK. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004 ; 75 : 330-7.
 
9) Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PI, Le JM, Lee HS, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gregersen PK. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007 ; 357 (10) : 977-86.
PubMed
10) Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, Liew A, Khalili H, Chandrasekaran A, Davies LR, Li W, Tan AK, Bonnard C, Ong RT, Thalamuthu A, Pettersson S, Liu C, Tian C, Chen WV, Carulli JP, Beckman EM, Altshuler D, Alfredsson L, Criswell LA, Amos CI, Seldin MF, Kastner DL, Klareskog L, Gregersen PK. TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N Engl J Med 2007 ; 357 (12) : 1199-209.
 
11) Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, Ohtsuki M, Furukawa H, Yoshino S, Yukioka M, Tohma S, Matsubara T, Wakitani S, Teshima R, Nishioka Y, Sekine A, Iida A, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003 ; 34 (4) : 395-402.
PubMed
12) Barton A, Bowes J, Eyre S, Spreckley K, Hinks A, John S, Worthington J.A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. Arthritis Rheum 2004 ; 50 (4) : 1117-21.
 
P.21 掲載の参考文献
1) Lanchbury JS, Panayi GS. Genetics of RA : the HLA shared epitope hypothesis and its implications. Br J Rheumatol 1991 ; 30 Suppl 2 : 6-9.
 
2) Luross JA, Heaton T, Hirst TR, Day MJ, Williams NA. Escherichia coli heat-labile enterotoxin B subunit prevents autoimmune arthritis through induction of regulatory CD4+ T cells. Arthritis Rheum 2002 ; 46 (6) : 1671-82.
PubMed
3) Knight B, Katz DR, Isenberg DA, Ibrahim MA, Le Page S, Hutchings P, Schwartz RS, Cooke A. Induction of adjuvant arthritis in mice. Clin Exp Immunol 1992 ; 90 (3) : 459-65.
PubMed
4) Hasunuma T, Sumida T, Nishioka K. Human T cell leukemia virus type-I and rheumatoid arthritis. Int Rev Immunol 1998 ; 17 (5-6) : 291-307.
 
5) Yoshitomi H, Sakaguchi N, Kobayashi K, Brown GD, Tagami T, Sakihama T, H irota K, Tanaka S, Nomura T, Miki I, Gordon S, Akira S, Nakamura T, Sakaguchi S. A role for fungal ｛beta｝-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J Exp Med 2005 21 ; 201 (6) : 949-60.
 
6) Kawahito Y, Ichinose S, Sano H, Tsubouchi Y, Kohno M, Yoshikawa T, Tokunaga D, Hojo T, Harasawa R, Nakano T, Matsuda K. Mycoplasma fermentans glycolipid-antigen as a pathogen of rheumatoid arthritis. Biochem Biophys Res Commun 2008 ; 369 (2) : 561-6.
PubMed
7) Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, Mikuls TR, Venables PJ. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and crossreact with bacterial enolase. Arthritis Rheum 2008 ; 58 (10) : 3009-19.
PubMed
8) Iwakura Y, Tosu M, Yoshida E, Takiguchi M, Sato K, Kitajima I, Nishioka K, Yamamoto K, Takeda T, Hatanaka M, Yamamoto H, Sekiguchi T. Induction of inflammatory arthropat hyresembling rheumatoid arthritis in mice transgenic for HTLV-I. Science 1991 ; 30 ; 253 (5023) : 1026-8.
 
9) Alspaugh MA, Jensen FC, Rabin H, Tan EM. Lymphocytes transformed by Epstein-Barr virus. Induction of nuclear antigen reactive with antibody in rheumatoid arthritis. J Exp Med 1978 ; 147 (4) : 1018-27.
PubMed
10) Takahashi Y, Murai C, Ishii T, Sugamura K, Sasaki T. Human parvovirus B19 in rheumatoid arthritis. Int Rev Immunol 1998 ; 17 (5-6) : 309-21.
 
11) Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, Ronnelid J, Harris HE, Ulfgren AK, Rantapaa-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L. A new model for an etiology of rheumatoid arthritis : Smoking may trigger HLA-DR (shared epitope) -restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006 ; 54 (1) : 38-46.
PubMed
12) Henrik Kallberg, Leonid Padyukov, Robert M. Plenge, Johan Ronnelid, Peter K. Gregersen, Annette H. M. van der Helm-van Mil, Rene E. M. Toes, Tom W. Huizinga, Lars Klareskog, Lars Alfredsson, and Epidemiological Investigation of Rheumatoid Arthritis (EIRA) Study Group. Gene-Gene and Gene-Environment Interactions Involving HLA-DRB1, PTPN22, and Smoking in Two Subsets of Rheumatoid Arthritis Am J Hum Genet 2007 ; 80 (5) : 867-875
 
13) Klareog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009 ; 21 ; 373 (9664) : 659-72
 

2. 関節リウマチ診療における検査

P.27 掲載の参考文献
1) Cimerman N, Brguljan PM, Krasovec M, Suskovic S, Kos J. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta 2000 ; 300 : 83-95.
PubMed
2) Poge U, Gerhardt T, Stoffel-Wagner B, et al. Cystatin C-based calculation of glomerular filtration rate in kidneytransplant recipients. Kidney Int 2006 ; 70 : 204-10.
 
3) Kazama JJ, Kutsuwada K, Ataka K, Maruyama H, Gejyo F. Serum cystatin C reliably detects renal dysfunctionin patients with various renal diseases. Nephron 2002 ; 91 : 13-20.
 
P.28 掲載の参考文献
1) Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE ; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008 ; 59 (6) : 762-84.
PubMed
2) Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after Infliximab in a patient with hepatitis B virus treated for an adultonset Still's disease. J Rheumatol 2003 ; 30 : 1624-5.
 
3) 坪内博仁, 坪内博仁, 熊田博光, 清澤研道, 持田智, 坂井田功, 田中榮司, 市田隆文, 溝上雅史, 鈴木一幸, 與芝眞彰, 森脇久隆, 日比紀文, 林紀夫, 國土典宏, 藤澤知雄, 石橋大海, 菅原寧彦, 八橋弘, 井戸章雄, 滝川康裕, 井上和明, 桶谷真, 宇都浩文, 中山伸朗, 内木隆文,多田慎一郎, 木曽真一, 矢野公士, 遠藤龍人, 田中靖人, 梅村武司, 熊谷公太郎. 免疫抑制・化学療法により発症するB型肝炎対策-厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告-. 肝臓 2009 ; 50 (1) : 38-42.
 
4) Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, Triolo G, Valentini G, Valesini G ; GISEA Group. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008 ; 35 (10) : 1944-9.
PubMed
5) Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis. B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases : assessment and preventive strategies. Ann Rheum Dis 2006 ; 65 (8) : 983-9.
PubMed
P.31 掲載の参考文献
1) Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis : a systematic literature review. Ann Rheum Dis 2006 ; 65 (7) : 845-51.
PubMed
2) 宮村知也, 渡邉秀之, 高濱宗一郎, 園本格士朗, 中村真隆, 安藤仁, 南留美, 山本政弘, 末松栄一. 早期関節リウマチの診断における抗環状シトルリン化ペプチド抗体 (抗CCP抗体) の有用性の検討. 日本臨床免疫学会会誌 2009 ; 32 (2) : 102-9
 
3) Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis : a systematic literature review. Ann Rheum Dis 2006 ; 65 (7) : 845-51.
PubMed
4) Emery P. Treatment of rheumatoid arthritis. BMJ 2006 ; 21 ; 332 (7534) : 152-5.
 
P.32 掲載の参考文献
1) Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, Kamatani N. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000 ; 43 (4) : 852-8.
PubMed
1) 熊谷俊一, 西村邦宏, 林伸英. 免疫検査の最近の話題 (2), 関節リウマチ. 臨床病理 2004 ; 52 (10) : 836-43.
 
2) 林伸英, 熊谷俊一. リウマチ診断のための新しい検査. 臨床病 2003 ; 51 (10) : 1030-35.
 
3) Ribbens C, Martiny Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases : relationship with synovitis and steroid treatment. Ann Rheum Dis 2002 ; 61 (2) : 161-6.
 
4) 山田俊之. マトリックスメタロプロテイナーゼ-3 Lab Clin Pract 2003 ; 21 (2) : 85-8.
 
P.34 掲載の参考文献
1) McQueen FM, Ostendorf B. What is MRI bone oedema in rheumatoid arthritis and why does it matter? Arthritis Res Ther 2006 ; 8 (6) : 222.
PubMed
2) A McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, McLean L. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998 ; 57 (6) : 350-6.
PubMed
3) Koenig H, Lucas D, Meissner R. The wrist : a preliminary report on high-resolution MR imaging. Radiology. 1986 ; 160 (2) : 463-7.
 
4) Wakefield RJ, Kong KO, Conaghan PG, Brown AK, O'Connor PJ, Emery P. The role of ultrasonography and magnetic resonance imaging in early rheumatoid arthritis. Clin Exp Rheumatol 2003 ; 21 (5 Suppl 31) : S42-9.
 
5) McQueen FM, Benton N, Crabbe J, Robinson E, Yeoman S, McLean L, Stewart N. What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x rays and magnetic resonance imaging over the first twoyears of disease. Ann Rheum Dis 2001 ; 60 (9) : 859-68.
 
6) Bird P, Conaghan P, Ejbjerg B, McQueen F, Lassere M, Peterfy C, Edmonds J, Shnier R, O'Connor P, Haavardsholm E, Emery P, Genant H, Ostergaard M. The development of the EULAROMERACT rheumatoid arthritis MRI reference image atlas. Ann Rheum Dis 2005 ; 64 : Suppl 1 : i8-10.
 
P.35 掲載の参考文献
1) Wakefield RJ, Kong KO, Conaghan PG, Brown AK, O'Connor PJ, Emery P. The role of ultrasonography and magnetic resonance imaging in early rheumatoid arthritis. Clin Exp Rheumatol 2003 ; 21 (5 Suppl 31) : S42-9.
 

3. 活動性や病期の評価法

P.40 掲載の参考文献
1) van der Heijde DMFM, van't Hof MA, van Riel PLCM, Theunisse HAM, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LBA. Judging disease activity in clinical practice in rheumatoid arthritis. First step in the development of a 'disease activity score'. Ann Rheum Dis 1990 ; 49 : 916-2040.
 
1) Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949 ; 140 : 659-62.
PubMed
2) Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977 ; 18 : 481-91.
PubMed
2) Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995 ; 38 (1) : 44-8.
 
3) Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983 ; 26 : 1346-53.
PubMed
4) Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS) 28-erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 2007 ; 66 (3) : 407-9.
PubMed
P.43 掲載の参考文献
1) Meenan RF, Mason JH, Anderson JJ, Guccione AA, Kazis LE. AIMS2 : The content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire. Arthritis Rheum 1992 ; 35 : 1-10.
PubMed
2) Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992 ; 30 : 473-83.
PubMed
3) Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983 ; 26 : 1346-53.
PubMed
P.45 掲載の参考文献
1) Daniel Aletaha, Josef S. Smolen. Arthritis Rheum 2011 ; 62 (10 Suppl) : S29.
 
2) Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M. American College of Rheumatology ; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011 ; 63 (3) : 573-86. Ann Rheum Dis 2011 ; 70 (3) : 404-13.
 
3) van Tuyl LHD, Britsemmer K, Felson DT, Wells GA, Smolen JS, Zhang B, Funovitis J, Van Schaardenburg D, Boer M. Consequence of remission misclassification due to reduce joint counts omitting the forefeet. Arthritis Rheum 2011 ; 62 (10 Suppl) : S301-2.
 
P.46 掲載の参考文献
1) Huscher D, Thiele K, Bischoff S, Backhaus M, Thun M, Aringer M, Zink A. Performance of the new ACR/EULAR remission criteria compared to DAS28 remission in unselected real-life patients with rheumatoid arthritis. EULAR 2011 OP0312.
 
2) Vermeer M, Kuper H, van der Bijl A, Baan H, Posthumus M, Brus H, van Riel P, van de Laar M. The new ACR/EULAR definitions of remission in rheumatoid arthritis : is the patient global assessment criterion too strict? EULAR 2011 OP0311.
 
3) Shahouri SH, Michaud K, Mikuls TR, Caplan L, Shaver TS, Anderson JD, Weidensaul DN, Busch RE, Wang S, Wolfe F. Remission of rheumatoid arthritis in clinical practice : Application of the ACR/EULAR 2011 remission criteria. Arthritis Rheum 2011. doi : 10.1002/art.30524. [Epub ahead of print]
 

4. 関節リウマチの診断から治療戦略

P.49 掲載の参考文献
1) Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 ; 31 (3) : 315-24.
PubMed
1) Harris ED Jr. Etiology and pathogenesis of rheumatoid arthritis. In : Kelly E, Harris ED Jr, Ruddy SL, editors. Textbook of rheumatology. Vol. 1.4th ed. Philadelphia : W. B. Saunders ; 1993. Chap.51, p833.
 
2) Harris ED Jr. Clinical features of rheumatoid arthritis. In : Kelly E, Harris ED Jr, Ruddy SL, editors. Textbook of rheumatology. Vol. 1.4th ed. Philadelphia : W. B. Saunders ; 1993. Chap.52, p874.
 
3) Kavanaugh AF, Lipsly PE. Rheumatoid arthritis. In : Rich RR, Fleisher TA, Sheearer WT, Schwartz BD, Strober W. editors. Clinical Immunology : principles and practices. St Louis, MO : Mosby & Co. ; 1996, Chap.72, p1093.
 
4) Smyth CJ. Therapy of rheumatoid arthritis. A pyramidal plan. Postgrad Med 1972 ; 51 (6) : 31-9.
PubMed
5) van der Horst-Bruinsma IE, Speyer I, Visser H, et al. Diagnosis and course of early onset arthritis : results from a special early arthritis clinic compared to routine patient care. Br J Rheumatol 1998 ; 37 : 1084-8.
PubMed
6) Kaufmann J, Kielstein V, Kilian S, et al. Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol 2003 ; 30 : 2350-5.
PubMed
7) Machold KP, Stamm TA, Eberl GJ, Nell VK, Dunky A, Uffmann M, Smolen JS. Very recent onset arthritis--clinical, laboratory, and radiological findings during the firstyear of disease. J Rheumatol 2002 ; 29 : 2278-87.
 
8) Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, Uffmann M, Smolen JS.Very recent onset rheumatoid arthritis : clinical and serological patient characteristics associated with radiographic progression over the firstyears of disease. Rheumatology 2007 ; 46 : 342-9.
 
P.53 掲載の参考文献
1) Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 rheumatoid arthritis classification criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010 ; 69 (9) : 1580-8. Athritis & Rheum ; 62 (9) : 2569-81.
 
P.56 掲載の参考文献
1) van der Linden MP, Batstra MR, Bakker-Jonges L, et al. Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis : Is it sensible to look at levels of rheumatoid factor? Arthritis Rheum 2011 ; 63 : 1190-9.
 
P.58 掲載の参考文献
1) Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D ; T2T Expert Committee. Treating rheumatoid arthritis to target : recommendations of an international task force. Ann Rheum Dis 2010 ; 69 (4) : 631-7.
PubMed
P.64 掲載の参考文献
1) Eddy DM. Clinical decision making : from theory to practice. Designing a practice policy. Standards, guidelines, and options. JAMA 1990 ; 263 (22) : 3077, 3081, 3084.
PubMed
2) American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines Guidelines for the Management of Rheumatoid Arthritis 2002 Update Arthritis Rheum 2002 ; 6 (2) : 328-46
 
3) 関節リウマチの診療マニュアル (改訂版) 診断のマニュアルとEBMに基づく治療ガイドライン編集 越智隆弘, 山本一彦, 龍順之助, 発行日本リウマチ財団 2004 メジカルビュー p166
 
4) Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE ; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008 ; 15 ; 59 (6) : 762-84.
 
5) Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010 ; 69 (6) : 964-75.
PubMed
P.71 掲載の参考文献
1) Kirwan JR, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007 ; 24 : CD006356.
PubMed
2) Pincus T, Marcum SB, Callahan L. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices : II. Second line drugs and prednisolone. J Rheumatol 1992 ; 19 : 1885-94.
 

5. 日常リウマチ診療における対応

P.78 掲載の参考文献
1) Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA. Specific autoantibodies precede the symptoms of rheumatoid arthritis : a study of serial measurements in blood donors. Arthritis Rheum 2004 ; 50 (2) : 380-6.
PubMed
2) Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D ; T2T Expert Committee. Treating rheumatoid arthritis to target : recommendations of an international task force. Ann Rheum Dis 2010 ; 69 (4) : 631-7.
PubMed
3) van der Linden MP, Knevel R, Huizinga TW et al. Classification of rheumatoid arthritis : comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum 2011 ; 63 (1) : 37-22.
PubMed
4) Soubrier M, Puechal X, Sibilia J, Mariette X, Meyer O, Combe B, Flipo RM, Mulleman D, Berenbaum F, Zarnitsky C, Schaeverbeke T, Fardellone P, Dougados M. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis : data from the GUEPARD trial. Rheumatology (Oxford) 2009 ; 48 (11) : 1429-34
 
5) Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ ; British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis : results from a large UK national cohort study. Arthritis Rheum 2007 ; 56 (1) : 13-20.
PubMed
6) Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE ; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008 15 ; 59 (6) : 762-84.
 
7) Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010 ; 69 (6) : 964-75.
PubMed
8) Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. Presence of significant synovitis in rheumatoid arthritis patients with diseasemodifying antirheumatic drug-induced clinical remission : evidence from an imaging study may explain structural progression. Arthritis Rheum 2006 ; 54 (12) : 3761-73.
PubMed
9) Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008 ; 58 (10) : 2958- 67.
 
10) Saleem B, Keen H, Goeb V, Parmar R, Nizam S, Hensor EM, Churchman SM, Quinn M, Wakefield R, Conaghan PG, Ponchel F, Emery P. Patients with RA in remission on TNF blockers : when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010 ; 69 (9) : 1636-42.
PubMed
11) Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, Koike T ; RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010 ; 69 (7) : 1286-91.
 
12) Schipper LG, Fransen J, den Broeder AA, Van Riel PL. Time to achieve remission determines time to be in remission. Arthritis Res Ther 2010 ; 12 (3) : R97.
PubMed

6. 妊娠、授乳に関わる関節リウマチ治療

P.83 掲載の参考文献
1) Perselin R. The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis 1976-7 ; 27 (9) : 922-7.
 
2) Silman A, Kay A, Brennan P. (1992) Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum 1992 ; 35 : 152 : 152-5.
 
3) Barrett JH, Brennan P, Fiddler M, Silman AJ. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum 1999 ; 42 (6) : 1219-27.
PubMed
4) de Man YA, Dolhain RJ, van de Geijn FE, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during pregnancy : results from a nationwide prospective study. Arthritis Rheum 2008 ; 15 ; 59 (9) : 1241-8.
 
5) Ostensen M. New insights into sexual functioning and fertility in rheumatic diseases. Best Pract Res Clin Rheumatol 2004 ; 18 (2) : 219-32
 
6) Keeling SO, Oswald AE. Pregnancy and rheumatic disease : "by the book" or "by the doc". Clin Rheumatol 2009 ; 28 (1) : 1-9.
PubMed
7) Wallenius M, Skomsvoll JF, Irgens LM, Salvesen KA, Koldingsnes W, Mikkelsen K, Kaufmann C, Kvien TK. Postpartum onset of rheumatoid arthritis and other chronic arthritides : results from a patient register linked to a medical birth registry Ann Rheum Dis 2010 ; 69 : 332-6
 
8) Queisser-Luft A, Eggers I, Stolz G, Kieninger-Baum D, Schlaefer K. Serial examination of 20,248 newborn fetuses and infants : correlations between drug exposure and major malformations. Am J Med Genet 1996 ; 63 (1) : 268-76.
PubMed
9) Florescu A, Koren G. Nonsteroidal anti-inflammatory drugs for rheumatoid arthritis during pregnancy. Can Fam Physician. 2005 ; 51 : 961-2.
PubMed
10) Ericson K, Kallen BAJ. Non-steroidal antiinflammatory drugs in early pregnancy. Reprod Toxicol 2001 ; 15 : 371-5.
 
11) Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Kasapinovic S, Chang D, Diav-Citrin O, Chitayat D, Nulman I, Einarson TR, Koren G. Birth defects after maternal exposure to corticosteroids : prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000 ; 62 (6) : 385-92.
PubMed
12) Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies : a collaborative randomized trial comparing prednisone with lowdose heparin treatment. Am J Obstet Gynecol 1992 ; 166 (5) : 1318-23.
PubMed
13) Norgard B, Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 2001 ; 15 (4) : 483-6.
PubMed
14) 川人豊, 吉川敏一, 内藤裕二, 高橋周史, 小山田裕一, 上田茂信, 田井中憲三, 竹村俊樹, 森田豊, 谷川徹, 粉川隆文, 杉野成, 近藤元治. 潰瘍性大腸炎と妊娠. 京都府立医科大学雑誌 1990 ; 99 (6) : 695-702.
 
15) Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000 ; 343 (22) : 1608-14.
PubMed
16) Feldkamp M, Carey JC. Teratology. Clinical teratology counseling and consultation case report : low dose methotrexate exposure in the early weeks of pregnancy. 1993 ; 47 (6) : 533-9.
PubMed
17) Ostensen M, Forger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol 2009 ; 5 (7) : 382-90.
PubMed
18) Cush JJ. Biological drug use : US perspectives on indications and monitoring. Ann Rheum Dis 2005 ; 64 Suppl 4 : iv18-23.
 

7. 血管炎を伴う関節リウマチと関節外症状

P.86 掲載の参考文献
1) Gorman JD, David-Vaudey E, Pai M, Lum RF, Criswell L A. L ack o f association of the HLA-DRB1 shared epitope with rheumatoid nodules : an individual patient data meta-analysis of 3,272 Caucasian patients with rheumatoid arthritis. Arthritis Rheum 2004 ; 50 (3) : 753-62.
 
2) 京極方久 ; 悪性関節リウマチの病理学的特徴 リウマチ 1975 ; 15 : 483-7.
 
3) 橋本博史, 安倍達, 延永正, 他. 悪性関節リウマチの改訂診断基準の提唱 リウマチ 1989 ; 29 : 268-76.
 
4) Bartels CM, Bridges AJ. Rheumatoid vasculitis : vanishing menace or target for new treatments? Curr Rheumatol Rep 2010 ; 12 (6) : 414-9.
PubMed
5) Fujii W, Kohno M, Ishino H, Nakabayashi A, Fujioka K, Kida T, Nagahara H, Murakami K, Nakamura K, Seno T, Yamamoto A, Kawahito Y. The rapid efficacy of abatacept in a patient with rheumatoid vasculitis. Mod Rheumatol (in press).
 
P.88 掲載の参考文献
1) 中野正明, 山田俊幸, 小沢哲夫, 他. 生検診断によるアミロイドーシス合併慢性関節リウマチの臨床的検討. リウマチ 1989 ; 29 : 251-8.
 
2) Okuda Y, Takasugi K. Diaganosotic and prognostic study of secondary amyloidosis complicating rheumatoid arthritis. Amyloid and Amyloidosis. Parthenon Publishing Group, New York 1998 ; 426-8.
 
3) 豊島元, 草場公宏, 山口雅也. 剖検輯法からみた慢性関節リウマチの死因 : 特にアミロイドーシスとの関連から. リウマチ 1991 ; 31 : 96-111.
 
4) 奥田恭章. 関節リウマチに合併したAAアミロイドーシスの診断と治療. 臨床リウマチ 2006 ; 18 : 291-7.
 
5) 川人豊. 関節リウマチにおける消化管病変. 臨床リウマチ 2007 ; 19 (1) : 11-6.
 
6) 奥田恭章, 高杉潔, 小山徹, 小沼正和, 小山宏子. 慢性関節リウマチ (RA) に合併した2次性アミロイドーシス124例の臨床的検討 胃十二指腸生検による診断と予後を中心として. リウマチ 1994 ; 34 : 939-46.
 
7) Kuroda T, Tanabe N, Sakatsume M, Nozawa S, Mitsuka T, Ishikawa H, Tohyama CT, Nakazono K, Murasawa A, Nakano M, Gejyo F. Comparison of gastroduodenal, renal and abdominal fat biopsies for diagnosing amyloidosis in rheumatoid arthritis. Clin Rheumatol 2002 ; 2 : 123-8.
PubMed
8) Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001 ; 358 (9275) : 24-9.
PubMed
9) Fernandez-Nebro A, Olive A, Castro MC, Varela AH, Riera E, Irigoyen MV, Garcia de Yebenes MJ, Garcia-Vicuna R. Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med 2010 ; 123 (5) : 454-61.
PubMed
10) Nishida S, Hagihara K, Shima Y, Kawai M, Kuwahara Y, Arimitsu J, Hirano T, Narazaki M, Ogata A, Yoshizaki K, Kawase I, Kishimoto T, Tanaka T. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis 2009 ; 68 (7) : 1235-6.
PubMed
11) Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puechal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M ; Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007 ; 356 (23) : 2349-60.
PubMed
P.89 掲載の参考文献
1) Fewins HE, McGowan I, Whitehouse GH, Williams J, Mallya R. High definition computed tomography in rheumatoid arthritis associated pulmonary disease. Br J Rheumatol 1991 ; 30 (3) : 214-6
 
2) Anaya JM, Diethelm L, Ortiz LA, Gutierrez M, Citera G, Welsh RA, Espinoza LR. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 1995 ; 24 (4) : 242-54.
PubMed
P.91 掲載の参考文献
1) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. American Thoracic Society ; European Respiratory Society. Am J Respir Crit Care Med 2002 ; 165 (2) : 277-304.
PubMed
2) 日本呼吸器病学会. 薬剤性肺障害の評価, 治療についてのガイドライン. メディカルレビュー社 2006
 
3) 槇野茂樹. 関節理町と薬剤性肺炎. 臨床リウマチ 2008 ; 20 : 76-80.
 
4) 田中良一. 関節リウマチと肺合併症 まとめ. 臨床リウマチ 2008 ; 20 : 81-9.
 
5) Miyata M, Sakuma F, Fukaya E, Kobayashi H, Rai T, Saito H, Kasukawa R, Suzuki S. Detection and monitoring of methotrexate-associated lung injury using serum markers KL-6 and SP-D in rheumatoid arthritis. Intern Med 2002 ; 41 (6) : 467-73.
PubMed
6) Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, Kamatani N, Harigai M, Ryu J, Inoue K, Kondo H, Inokuma S, Ochi T, Koike T. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008 ; 67 (2) : 189-94.
PubMed
7) Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, Suzukawa M. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009 ; 36 (5) : 898-906.
PubMed
8) Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Tanaka Y. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients : postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 2011 Oct 13. [Epub ahead of print]
 
9) Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Ito K, Yamanaka H. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan : interim analysis of 3881 patients. Ann Rheum Dis 2011 ; 70 (12) : 2148-51.
PubMed
P.92 掲載の参考文献
1) Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 ; 345 (15) : 1098-104.
PubMed
2) Ehlers S.Tumor necrosis factor and its blockade in granulomatous infections : differential modes of action of infliximab and etanercept? Clin Infect Dis 2005 ; 41 Suppl 3 : S199-203.
 
3) Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X ; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy : The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009 ; 60 (7) : 1884-94.
PubMed
4) Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A ; B S R B R Control Centre Consortium, Symmons DP ; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy : results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010 ; 69 (3) : 522-8.
 
5) Mori T. Usefulness of interferon-gamma release assays for diagnosing TB infection and problems with these assays. J Infect Chemother 2009 15 (3) : 143-55.
PubMed
6) Hotta K, Ogura T, Nishii K, Kodani T, Onishi M, Shimizu Y, Kanehiro A, Kiura K, Tanimoto M, Tobe K. Whole blood interferon-gamma assay for baseline tuberculosis screening among Japanese healthcare students. PLoS One 2007 ; 2 (8) : e803.
PubMed
P.95 掲載の参考文献
1) Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K ; ATS Mycobacterial Diseases Subcommittee ; American Thoracic Society ; Infectious Disease Society of America. : An official ATS/IDSA statement : diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007 ; 175 (4) : 367-416.
PubMed
2) 日本結核病学会非結核性抗酸菌症対策委員会. 肺非結核性抗酸菌症診断に関する指針-2008年. 結核 2008 ; 83 : 525.
 
3) 日本結核病学会非結核性抗酸菌症対策委員会. 肺非結核性抗酸菌症化学療法に関する見解-2008暫定. 結核 2008 ; 83 : 731.
 
P.96 掲載の参考文献
1) 中野正明. 全身性疾患と腎病変 診断と治療の進歩 膠原病 関節リウマチの腎障害に対する留意点. 日本内科学会雑誌 2005 ; 94 (5) : 859-63.
 

8. リウマチ診療における抗炎症薬とステロイドの使い方

P.101 掲載の参考文献
1) Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, Hui AJ, Leung VK, Lee VW, Lai LH, Wong GL, Chow DK, To KF, Leung WK, Chiu PW, Lee YT, Lau JY, Chan HL, Ng EK, Sung JJ. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk : a double-blind, randomised trial. Lancet 369 : 1621-6, 2007.
 
2) Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, Chan HL, Sung JJ. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking lowdose aspirin or naproxen. N Engl J Med 344 : 967-73, 2001.
PubMed
3) Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG ; Investigators. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005 ; 3 (2) : 133-41.
PubMed
4) Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol 1996 ; 35 Suppl 1 : 4-12.
 
5) Weideman RA, Kelly KC, Kazi S, Cung A, Roberts KW, Smith HJ, Sarosi GA, Little BB, Cryer B. Risks of clinically significant upper gastrointestinal events with etodolac and naproxen : a historical cohort analysis. Gastroenterology 2004 ; 127 (5) : 1322-8.
PubMed
6) Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs : population based study. BMJ 2005 ; 330 (7504) ; 1370.
PubMed
7) Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. : Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001 ; 345 (25) : 1809-17.
PubMed
8) Anzellotti P, Capone ML, Jeyam A, Tacconelli S, Bruno A, Tontodonati P, Di Francesco L, Grossi L, Renda G, Merciaro G, Di Gregorio P, Price TS, Garcia Rodriguez LA, Patrignani P. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects : recommendations to minimize the functional consequences. Arthritis Rheum 2011 ; 63 (3) : 850-9
PubMed
9) Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999 Jun 17 ; 340 (24) : 1888-99.
 
10) Scheiman JM. Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases.Drugs 2006 ; 66 Suppl 1 : 15-21 ; discussion 29-33.
 
P.104 掲載の参考文献
1) American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis : 2002 Update. Arthritis Rheum 2002 ; 46 (2) : 328-46.
PubMed
2) ACR subcomittee arthritis Guidline.Guidlines for the Management of Rheumatoid Arthritis. Arthritis Rheum 2002 ; 46 : 328-346.
 
P.105 掲載の参考文献
1) Kumagai A, Morimoto Y,Yamamura Y. : Major side effects of glucocorticoids in Japan. Endocrinol Japan 1965 ; 12 : 36-46.
PubMed
2) 西川光男. 副腎皮質ホルモンによるIatrogenic disease. 日本内分泌学会雑誌 1965 ; 41 : 842-52.
 
3) 高岡義人. ホルモン製剤による医原性疾患. 内科 1967 ; 19 : 485-91.
 
4) Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, Zink A, Buttgereit F. Doserelated patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009 ; 68 (7) : 1119-24.
PubMed
P.107 掲載の参考文献
1) Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989 ; 11 : 954-63.
PubMed
2) 市川陽一. 全身性エリテマトーデスの予後因子と治療. 日本維持新報 1987 ; 3332 : 3-11.
 
3) Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia : associations with prednisone, disease-modifying antirheumatic drugs, and antitumor necrosis factor therapy. Arthritis Rheum 2006 ; 54 : 628-34.
PubMed
4) Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome : associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996 ; 71 : 5-13.
PubMed
5) Harigai M, Koike R, Miyasaka N ; Pneumocystis Pneumonia under Anti-Tumor Necrosis Factor Therapy (PAT) Study Group. : Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007 ; 357 : 1874-6.
 
P.108 掲載の参考文献
1) 並木正義 : 胃粘膜防御機構の縦走構造 (竹本忠良編) メディカルトリビューン社 1987 p50
 
2) 川人豊. グルココルチコイド治療と消化管障害 リウマチ科 2011 ; 41 (3) : 228-31.
 
P.110 掲載の参考文献
1) van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis : a meta-analysis. Osteoporos Int 2002 ; 13 (10) : 777-87.
PubMed
2) Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis. Arthritis Care Res (Hoboken) 2010 ; 62 (11) : 1515-26.
PubMed
3) Bisphosphonate-Related Osteonecrosis of the Jaw : Position Paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Mi ner Metab (2010) 28, (DOI 10.1007/s00774-010-0162-7)
 
P.111 掲載の参考文献
1) Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994 10 ; 154 (1) : 97-101.
PubMed
2) Davis JM 3rd, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Therneau TM, Roger VL, Gabriel SE. Glucocorticoids and cardiovascular events in rheumatoid arthritis : a population-based cohort study. Arthritis & Rheumatism 2007 ; 56 : 820-30.
PubMed
3) Ichikawa Y, Toguchi T, Kawagoe M, Saito E, Abe T, Homma M. ECG abnormalities in steroid-treated rheumatoid patients. Lancet 1977 15 ; 2 (8042) : 828.
 

9. 生物学的製剤を含めた抗リウマチ薬の使用法

P.115 掲載の参考文献
1) Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996 ; 39 (12) : 1951-60.
PubMed
2) Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE ; American College of Rheumatology.American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008 : 15 ; 59 (6) : 762-84.
 
3) Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010 ; 69 (6) : 964-75.
PubMed
4) Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004 ; 31 (4) : 645-8.
PubMed
5) Seideman P. Methotrexate--the relationship between dose and clinical effect. Br J Rheumatol 1993 ; 32 (8) : 751-3.
PubMed
6) Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying antirheumatic drugs in clinical practice. QJM 2001 ; 94 (6) : 309- 19.
 
7) Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008 ; 58 (11) : 3299-308.
PubMed
P.117 掲載の参考文献
1) Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H, Ochiai T. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987 ; 40 (9) : 1256-65.
 
2) Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, Sugawara S. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis : a randomized, double blind, placebo controlled dose-finding study. J Rheumatol 2004 ; 31 (2) : 243- 51.
 
3) Kawai S, Takeuchi T, Yamamoto K, Tanaka Y, Miyasaka N. Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial. Mod Rheumatol 2011 ; 21 (5) : 458-68.
PubMed
4) Suzuki K, Saito K, Tsujimura S, Nakayamada S, Yamaoka K, Sawamukai N, Iwata S, Nawata M, Nakano K, Tanaka Y.Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. J Rheumatol 2010 ; 37 (3 ) : 512- 20.
 
P.118 掲載の参考文献
1) Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine : a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998 ; 101 (5) : 1163-74.
PubMed
1) Horwitz LD. Bucillamine : a potent thiol donor with multiple clinical applications. Cardiovasc Drug Rev 2003 ; 21 (2) : 77-90.
PubMed
2) Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, Oshima H, Kawai S, Hama N, Yamada H, Mimori T, Amano K, Tanaka Y, Matsuoka Y, Yamamoto S, Matsubara T, Murata N, Asai T, Suzuki Y ; MTX-BUC Combination Study Group ; Japanese Ministry of Health ; Labour and Welfare's "Research for Establishment of Therapeutic Guidelines in Early Rheumatoid Arthritis". Therapeutic effects of the combination of met hotrexate and bucillamine in early rheumatoid arthritis : a multicenter, double-blind, randomized controlled study. Mod Rheumatol 2005 ; 15 (5) : 323-8.
 
2) Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, Buckley MT, Carlin G, Cronstein BN. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996 ; 156 (5) : 1937-41.
 
3) Liptay S, Bachem M, Hacker G, Adler G, Debatin KM, Schmid RM. Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol 1999 ; 128 (7) : 1361-9.
 
P.119 掲載の参考文献
1) Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS. Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest. 1991 ; 87 (3) : 940-8.
PubMed
2) Ichinose K, Origuchi T, Kawashiri SY, Iwamoto N, Fujikawa K, Aramaki T, Kamachi M, Arima K, Tamai M, Nakamura H, Ida H, Kawakami A, Tsukada T, Ueki Y, Eguchi K. Efficacy and safety of mizoribine by one single dose administration for patients with rheumatoid arthritis. Intern Med 2010 ; 49 (20) : 2211-8.
PubMed
3) 福田亙, 柳田国雄, 井上衛, 坪内康則, 河野正孝, 川人豊, 吉川敏一. Methotrexateが効果不十分な関節リウマチ症例に対するMizoribineの高用量間歇追加投与の臨床的有用性 連日投与法との比較検討. 臨床リウマチ 2009 ; 21 (2) : 123-8.
 
P.120 掲載の参考文献
1) Jeon KI, Jeong JY, Jue DM. Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J Immunol 2000 ; 164 (11) : 5981- 9.
 
2) Rau R, Herborn G, Menninger H, Sangha O. Progression in early erosive rheumatoid arthritis : 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol 1998 ; 37 (11) : 1220-6.
PubMed
P.121 掲載の参考文献
1) Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide : an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000 ; 47 (2-3) : 273-89.
 
1) Nakamura H, Ueki Y, Sakito S, Matsumoto K, Yano M, Miyake S, Tominaga Y, Eguchi K. Clinical effects of actarit in rheumatoid arthritis : improvement of early disease activity mediated by reduction of serum concentrations of nitric oxide. Clin Exp Rheumatol 2000 ; 18 (4) : 445-50.
PubMed
P.122 掲載の参考文献
1) Furst DE, Lindsley H, Baethge B, Botstein GR, Caldwell J, Dietz F, Ettlinger R, Golden HE, McLaughlin GE, Moreland LW, Roberts WN, Rooney TW, Rothschild B, Sack M, Sebba AI, Weisman M, Welch KE, Yocum D. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis : a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum 1999 ; 42 (2) : 357-65.
PubMed
1) Nakamura H, Ueki Y, Sakito S, Matsumoto K, Yano M, Miyake S, Tominaga Y, Eguchi K. Clinical effects of actarit in rheumatoid arthritis : improvement of early disease activity mediated by reduction of serum concentrations of nitric oxide. Clin Exp Rheumatol 2000 Jul-Aug ; 18 (4) : 445-50.
 
2) A randomized trial of hydroxychloroquine in early rheumatoid arthritis : the HERA Study. Am J Med 1995 ; 98 (2) : 156-68.
PubMed
P.125 掲載の参考文献
1) Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN ; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000 ; 343 (22) : 1594-602.
 
2) Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T ; RISING study. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis : results from the RISING study. Mod Rheumatol 2009 ; 19 (5) : 478-87.
 
3) Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T, Koike T. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 2011 ; 70 (7) : 1208-15.
PubMed
4) Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, Seys PE, Huizinga TW, Dijkmans BA, Allaart CF. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011 ; 70 (6) : 1039-46.
PubMed
5) Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, Koike T ; RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010 ; 69 (7) : 1286-91.
 
P.126 掲載の参考文献
1) Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET) : a randomised, double-blind, parallel treatment trial. Lancet 2008 ; 372 (9636) : 375-82.
 
2) Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M ; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomised controlled trial.Lancet 2004 ; 363 (9410) : 675-81.
PubMed
3) Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Ostergaard M ; All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab : results from eightyears of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010 ; 62 (1) : 22-32.
PubMed
4) Smolen JS, Szumski A, MarshalL L, Koenig AS, Baseline predictors of remission with combination etanercept-methotrexate therapy in moderately active rheumatoid arthritis : Interim results of the PRESERVE Trial. Arthritis Rheum 2010 ; 63 (suppl 10) : S474.
 
P.127 掲載の参考文献
1) Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate : the ARMADA trial. Arthritis Rheum 2003 ; 48 : 35-45.
 
2) Weaver W. Efficacy and safety of the anti-TNF biologic agents. Mod Rheumatol 2004 14 : 101-12.
 
3) Takeuchi T. Anti-TNF biological agents in rheumatoid arthritis and other inflammatory diseases. Allergol Int 2005 ; 54 : 191-20.
 
4) Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study : A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006 ; 54 : 26-37.
 
5) Smolen JS, Fleischmann R, Emery P, Gue rette B, Patra K, Kupper H, Redden L, Kavanaugh A. The OPTIMA study of methotrexate and adlimumab : 78-week outcomes in early rheumatoid arthritis patients based on achieving a low DAS28 target after 26 weeks. Ann Rheum Dis 2011 ; 70 (Suppl 3) : 259
 
6) Emery P, Smolen JS, Kava naugh A, van Vollenhoven R, Pavelka K, Durez P, Guerette B, Redden L, Kupper H, Patra K, Fleischmann R. Maintenance of biologic-free disease control in early rheumatoid arthritis patients after induction of low disease activity with adalimumab plus methotorexate. Ann Rheum Dis 2011 ; 70 (Suppl 3) : 262
 
7) Tanaka Y, Hirata s, Nawata M, Kubo S, Saitoet K. Discontinuation of adalimumab after remission in patients with rheumatoid arthritis. Ann Rheum Dis 2011 ; 70 (Suppl 3) : 120.
 
P.128 掲載の参考文献
1) Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, Kanazawa M, Murakami Y,Yoshinari T, Baker DG, Miyasaka N, Koike T. 52-week results of clinical, radiographic and pharmacokinetic assessments : golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy. Arthritis Rheum 2011 ; 63 (suppl 10 ) ; S175.
 
2) Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, Kanazawa M, Murakami Y, Yoshinari T, Baker DG, Miyasaka N, Koike T. Golimumab, a human anti-TNF Monoclonal antibody, administered subcutaneously every four weeks as monotherapy in patients with active rheumatoid arthritis despite DMARD therapy : 52-week results of clinical, radiographic and pharmacokinetic assessments. Arthritis Rheum 2011 ; 63 (suppl 10) ; S176.
 
P.129 掲載の参考文献
1) Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP. The effect of antitumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008 ; 67 (5) : 713-6.
PubMed
1) Keystone E, Heijde D, Mason D Jr, Landewe R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis : findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008 ; 58 (11) : 3319-29.
 
2) Bernatsky S, Paterson M, Widdifield J, Pope J, Thorne C,Cividino A,Bombardier C. Rheumatoid arthritis (RA) and risk of serious infections : a nested case control study from the ONTARIO biologics research initiative (OBRI). Ann Rheum Dis 2010 ; 69 (Suppl 3) : 495.
 
2) Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis : the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009 ; 68 (6) : 797- 804.
 
P.131 掲載の参考文献
1) Japan College of Rheumatology Etanercept Post-Marketing, Surveillance Committee, Wyeth K. K., Medical Affairs, Osaka, Japan
 
2) Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, Kamatani N, Harigai M, Ryu J, Inoue K, Kondo H, Inokuma S, Ochi T, Koike T. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008 ; 67 (2) : 189-94.
PubMed
3) Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, Suzukawa M. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 2009 ; 36 (5) : 898-906.
PubMed
4) アダリムマブ 全例市販後調査
 
5) Harigai M, Koike R, Miyasaka N ; Pneumocystis Pneumonia under Anti-Tumor Necrosis Factor Therapy (PAT) Study Group. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007 ; 357 (18) : 1874-6.
 
P.132 掲載の参考文献
1) Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008 ; 10 (2) : R45.
PubMed
1) Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies : analysis of 233 cases. Medicine (Baltimore) 2007 ; 86 (4) : 242-51.
PubMed
2) Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, Hall S, Harkness A, Lewis D, Littlejohn G, Miller MH, Ryan PF, Jolley D. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008 ; 59 (6) : 794-9.
PubMed
3) Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy : analyses from a large US observational study. Arthritis Rheum 2007 56 (9) : 2886-95.
PubMed
4) Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, Listing J, Zink A. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010 ; 12 (1) : R5.
PubMed
5) Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Coster L, Geborek P, Jacobsson LT, Lindblad S, Rantapaa-Dahlqvist S, Saxne T, Klareskog L. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies : does the risk change with the time since start of treatment? Arthritis Rheum 2009 ; 60 (11) : 3180-9.
PubMed
P.133 掲載の参考文献
1) Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008 ; 58 (3) : 667-77.
PubMed
2) Solomon AJ, Spain RI, Kruer MC, Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler. 2011 Aug 3. [Epub ahead of print]
 
P.134 掲載の参考文献
1) Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI) : significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009 ; 19 (1) : 12-9.
 
2) Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI) : evidence of clinical and radiographic benefit from an x ray readerblinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007 ; 66 (9) : 1162-7.
 
3) Jones G, Ding C. Tocilizumab : a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2010 ; 3 : 81-9.
PubMed
P.135 掲載の参考文献
1) Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Ge Z, Becker JC, Westhovens R. Effects of abatacept in patients w ith methotrexate-resistant active rheumatoid arthritis : a randomized trial. Ann Intern Med 2006 ; 144 (12) : 865-76.
 
1) Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM ; IMAGE Investigators. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis : the IMAGE trial. Ann Rheum Dis 2011 ; 70 (1) : 39-46.
PubMed
2) Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST : a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008 ; 67 (8) : 1096-103.
PubMed
2) Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC ; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 ; 54 (9) : 2793-806.
PubMed
3) Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R. Adverse effects of biologics : a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011 ; (2) : CD008794.
PubMed

書評

最近チェックした商品履歴

Loading...